hpv vaers

australia was the first country to implement a fully funded vaccination program with quadrivalent human papillomavirus vaccine (4vhpv) in 2007, including males from 2013. we examined adverse events (ae) following vaccination with 4vhpv from 11 years of post-marketing data, focusing on a period of enhanced surveillance and adverse events of special interest (aesi). age and sex-specific rates, using denominator data from the national hpv vaccination register, were determined. the crude reporting rate was 39.8 per 100 000 doses in the funded cohorts, excluding the enhanced surveillance period.

the reported rate of syncope in 12 to 13-year-old males and females was 29.6 per 100 000 doses during enhanced surveillance and 7.1 per 100 000 doses during the remaining study period; rates of syncope were higher in younger compared to older adolescents. other aesi including autoimmune disease, postural orthostatic tachycardia syndrome, primary ovarian insufficiency, guillain-barrã© syndrome, complex regional pain syndrome and venous thromboembolism, were reported at low rates and analysis did not reveal unexpected patterns that would suggest causal association. analysis of this large, longitudinal dataset in a country with high vaccine uptake, including a period of enhanced surveillance, affirms the safety profile of 4vhpv. sciencedirect â® is a registered trademark of elsevier b.v.

overall, 30 states saw this type of increase in parental hesitancy to the hpv vaccine, according to the findings in jama network open. “these findings suggest an urgent need to combat the rising sentiment of safety concerns among caregivers to increase hpv vaccine confidence,” wrote sonawane and colleagues. hpv vaccination can prevent six types of cancer (vulvar, vaginal, cervical, penile, oropharyngeal, anal), the researchers noted, and the study is the first to present nationwide trends evaluating adverse events reporting. for their study, sonawane and colleagues conducted an analysis of vaers and the national immunization survey (nis), including data from 2015 to 2018. nis, performed by the cdc, consisted of a phone survey of adult caregivers’ reasons for hpv vaccine refusal, and included reports on 39,364 unvaccinated adolescents. nearly 80% of participants lived above the poverty line and over 60% had private insurance.

outside of safety concerns, the other top reasons for hpv vaccine hesitancy, as reported by 75% of caregivers, included being “not necessary,” “not recommended,” not having sexually active adolescents, and lacking knowledge on them. vaers, a spontaneous reporting system, often lacks subsequently relevant accompanying data, and is therefore subjected to bias, they added. source reference: sonawane k, et al “trends in human papillomavirus vaccine safety concerns and adverse event reporting in the united states” jama netw open 2021; doi: 10.1001/jamanetworkopen.2021.24502. the material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. medpage today is among the federally registered trademarks of medpage today, llc and may not be used by third parties without explicit permission.

have you had a reaction following a vaccination? contact your healthcare provider. report an adverse event using the vaers online form or the downloadable pdf. the vaccine adverse event reporting system (vaers) is an early warning system, co-managed by cdc and fda, that monitors for potential vaccine safety problems. between , vaers received a total of 275,595 vaccinated alone reports, including 171 for hpv2; from 2006 to 2018, there were 322,932, related conditions, related conditions.

like any vaccine or medicine, hpv vaccines can cause side effects. the most common side effects reported through cdc’s vaccine adverse event reporting system (vaers) are pain, redness, or swelling in the arm where the vaccine was given, dizziness, syncope (fainting), nausea, and headache. to look at trends in health issues reported after hpv vaccination, the researchers turned to the vaccine adverse event reporting system (vaers), hpv vaccination primarily aims to protect against cervical, the united states (us) vaccine adverse events reporting system (vaers) [37]. during 2015 to 2018, a total of 16 621 ae reports following hpv vaccination were reported to vaers. nonserious aes accounted for 95.4% (15 863), .

When you try to get related information on hpv vaers, you may look for related areas. related conditions.